ADMA Looks to Expand Asceniv's Label: Will This Boost Sales?
ADMA surges on soaring Asceniv demand and eyes pediatric label expansion to widen its immunodeficiency treatment reach.
ADMA Biologics: Slowing Growth Warrants A Shift To Neutral (Rating Downgrade)
ADMA's revenue growth has plateaued over the last three quarters, raising concerns about near-term momentum and justifying a shift to a neutral stance. Despite strong fundamentals and a promising long-term outlook, recent earnings misses and weak sequential sales make the current risk/reward profile less attractive. Given limited upside and better opportunities elsewhere, I have taken profits and will reconsider if quarter-over-quarter growth reaccelerates or the stock pulls back.
ADMA Stock Gains 17% in Three Months: Buy, Sell or Hold?
ADMA rises on strong Asceniv demand and boosted 2025-2026 guidance. However, valuation warrants investor caution.
ADMA Biologics vs. Grifols: Which Plasma Therapy Stock Is the Better Buy?
At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.
ADMA Biologics: Ready For More Growth Despite Q1 Earnings Miss
ADMA Biologics has demonstrated significant revenue growth, margin expansion, and profitability, leading to a 1,314% increase in share price since 2021. The company's Q1 performance showed a 40% YoY revenue increase, strong demand for ASCENIV, and improved gross profit margins. ADMA's financial health is robust, with $171M in cash and receivables, reduced debt costs, and a new $500M share repurchase program.
ADMA's Q1 Earnings and Revenues Miss: Buy, Sell or Hold the Stock?
ADMA Biologics misses on Q1 earnings and revenues. Nonetheless, the growth prospects remain strong as the company raises its revenue guidance for 2025.
ADMA Biologics, Inc. (ADMA) Q1 2025 Earnings Call Transcript
ADMA Biologics, Inc. (NASDAQ:ADMA ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - Founder, Director, President and Chief Executive Officer Brad Tade - Chief Financial Officer and Treasurer Conference Call Participants Anthony Petrone - Mizuho Group Rick Miller - Cantor Fitzgerald Gary Nachman - Raymond James Operator Good afternoon and welcome to the ADMA Biologics First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 7, 2025. At this time, all participants are in a listen-only mode.
Adma Biologics (ADMA) Misses Q1 Earnings and Revenue Estimates
Adma Biologics (ADMA) came out with quarterly earnings of $0.14 per share, missing the Zacks Consensus Estimate of $0.16 per share. This compares to earnings of $0.08 per share a year ago.
3 Mid-Cap Medical Stocks Outperforming the Market
While major market indexes like the S&P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and biotechnology sector mid-cap stocks have stood out for their resilience and outperformance.
Take the Zacks Approach to Beat the Markets: ADMA Biologics, Limbach, Quest Diagnostics in Focus
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
Adma Biologics (ADMA) Increases Yet Falls Behind Market: What Investors Need to Know
Adma Biologics (ADMA) concluded the recent trading session at $23.52, signifying a +1.07% move from its prior day's close.
Should ADMA Biologics Stock Be in Your Portfolio Pre-Q1 Earnings?
Strong performance of Asceniv continues to boost ADMA. We recommend the stock to investors due to its solid long-term fundamentals.
